Scientific credibility is established through peer-reviewed data and regulatory approval. Commercial credibility is established through payer coverage, provider adoption, and revenue performance. FDA approval transfers scientific credibility but does not automatically transfer commercial credibility. A majority of late-stage life sciences companies miss revenue expectations within 12 months of approval, according to McKinsey and IQVIA research, because commercial credibility was not built in parallel with the clinical program. The 18 to 24 month payer and provider uptake delay after approval is where most value destruction occurs.
- A majority of late-stage companies miss revenue expectations within 12 months of approval (McKinsey/IQVIA).
- FDA-approved platforms face 18-24 month delays in payer and provider uptake (strategicgrowthai.com).
- Market cap erosion from reimbursement delays reaches hundreds of millions for mid-cap biotechs annually.
- Scientific credibility and commercial credibility require parallel investment, not sequential.
- Payer engagement must begin 18-24 months before approval to compress the post-approval uptake window.
- Investors and pharma partners evaluate commercial credibility alongside scientific data.
The approval milestone that is not a launch
The FDA approval announcement goes out. The company's valuation peaks on the news. The team that has spent seven years and hundreds of millions of dollars to reach this moment celebrates a genuine scientific achievement.
Twelve months later, revenue is 40% below the launch forecast. The payer coverage conversations that everyone assumed would be straightforward post-approval are taking longer than expected. The prescriber adoption curve is slower than the analysts modeled. The stock has given back most of the approval-day gain.
This is not a rare scenario. It is the modal outcome for first-in-class and specialty products at companies that treated the approval as the commercial starting line rather than the midpoint of a commercial program that should have begun years earlier.
Commercialization risk data: strategicgrowthai.com, 2025 Guide to Reducing Life Science Commercialization Risk
Two kinds of credibility that do not transfer automatically
Scientific credibility and commercial credibility are distinct assets. They are built through different activities, by different audiences, and over different timelines. Conflating them is the most common strategic error in life sciences commercial planning.
How it is built
Peer-reviewed publications, clinical trial results, regulatory submission and approval, endorsement by key opinion leaders in the therapeutic area, conference presentations at medical society meetings. Built over 5 to 10 years. Audience: regulators, scientific community, physician specialists.
How it is built
Payer coverage and formulary placement, prescriber adoption data, patient access documentation, real-world evidence of outcomes in practice settings, health economics evidence, managed care contracting. Built over 2 to 5 years of active commercial investment. Audience: payers, managed care organizations, hospital pharmacy committees, primary care prescribers.
The FDA evaluates scientific credibility. Payers evaluate commercial credibility. Prescribers need both. The company that has only built scientific credibility by the time of approval arrives at commercial launch without the infrastructure that drives payer coverage and prescriber adoption.
Where the 18 to 24 month delay comes from
The post-approval uptake delay documented in the strategicgrowthai.com commercialization risk guide, drawing on McKinsey and IQVIA data, is not administrative delay. It is the consequence of a sequence problem: commercial credibility activities that should have begun 18 to 24 months before approval were not initiated until after approval, meaning the entire uptake clock starts at zero on approval day rather than being already advanced by two years of parallel work.
Payer engagement is the most visible example. The payer coverage dossier, the health economics and outcomes research that supports the coverage argument, the payer advisory board input that shapes the coverage story, and the initial conversations with major national and regional payers all require 12 to 18 months of lead time before approval to produce a coverage decision within 6 months of launch. Companies that start payer engagement at approval face a 12 to 18 month coverage gap that directly suppresses the revenue ramp.
Prescriber adoption follows the same logic. Prescribers who have been following the clinical program, attending disease state education events, and building familiarity with the mechanism and patient profile adopt at launch. Prescribers who receive a detail call at approval have the same information as prescribers who were actively educated over 18 months, but their adoption curve is 12 months behind.
What investors and pharma partners actually see
The commercial credibility gap is not only a post-approval problem. It affects how investors and pharma partners evaluate the company at every stage before approval.
An investor evaluating a pre-commercial biotech at Series C is not only assessing the clinical data. They are assessing whether the team understands what commercial execution requires. A company that has strong Phase 2 data and no payer engagement strategy, no health economics evidence plan, and no commercial infrastructure in place is signaling execution risk to any investor who has seen post-approval commercial failures.
Pharma partners conducting business development due diligence make the same assessment. The scientific case for the asset is evaluated by their clinical team. The commercial case is evaluated by their BD and commercial teams. A biotech that cannot articulate its coverage strategy, its prescriber targeting approach, and its launch sequencing is presenting an incomplete asset regardless of the scientific data quality.
For life sciences companies building commercial credibility alongside their clinical program, or identifying where the commercial credibility gaps are before approaching partners and investors, the strategy engagement maps the current position and the 18-month program to close the gaps. The full approach is at sfmarketing.agency/for/life-sciences.